Google DeepMind unveils SynthID Bio, a new watermarking technology designed for AI-created proteins that does not compromise their biological functions. Discover the full details in their research report.
The European Commission has increased its investment in the flagship research and innovation programme by an additional €500 million, bringing the total budget to approximately €14.8 billion. This significant funding boost aims to further support advancements in key sectors such as biodiversity and artificial intelligence.
Federal health authorities are launching new strategies to enhance the pace of clinical research, aiming to stay competitive on a global scale, especially against countries like China.
EliseAI has successfully raised $350 million, doubling its valuation to $4 billion within just one year.
OpenAI is reportedly negotiating its final funding round, aiming to raise $30 billion at a valuation of $1.4 trillion ahead of its postponed public offering in 2027.
Companies can now develop OpenAI-powered agents that run completely within Amazon Web Services, ensuring their data remains securely inside AWS. This new capability, launched during OpenAI’s DevDay 2026 in San Francisco, is part of the Bedrock Managed Agents offering created by OpenAI in partnership with Amazon. Currently, this product is available in a limited preview, enabling businesses to leverage advanced AI agents without their data ever leaving the AWS environment.
Beam Therapeutics claims that one of its scientists misappropriated proprietary gene-editing technology to establish a Chinese biotech company, which has subsequently secured venture capital investment.
At a MAHA Institute event, Kennedy and other experts emphasized the importance of making health data more accessible. They highlighted how unlocking this data can accelerate research on vaccines, chronic diseases, and autism, ultimately benefiting public health outcomes.
Anthropic has disclosed in its confidential IPO prospectus that advanced artificial intelligence may present extreme risks, including existential dangers, to humanity. The revelation, reported by Reuters and the Financial Times, comes as the AI startup prepares for a potential valuation of $2 trillion. This cautionary message aligns with the company’s earlier appeal to slow down AI development, a stance supported by other industry leaders such as OpenAI's Sam Altman and Elon Musk.
Modal Labs, the AI infrastructure provider, is on track to secure a $750 million funding round that would more than triple its valuation from just four months ago, now reaching $15.75 billion.
